Literature DB >> 6412620

Plasma concentrations of sodium valproate: their clinical value.

D M Turnbull, M D Rawlins, D Weightman, D W Chadwick.   

Abstract

Plasma valproate concentrations were monitored prospectively in 54 previously untreated adult patients with epilepsy. Dose and plasma concentration were highly correlated. Adverse effects were common in association with plasma levels above 100 micrograms/ml. In patients suffering tonic-clonic seizures without focal symptoms, no seizures occurred when plasma levels were higher than 50 micrograms/ml. In patients with partial seizures, it was difficult to define a lower limit to a therapeutic range.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6412620     DOI: 10.1002/ana.410140107

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  15 in total

1.  Conventional and sustained-release valproate in children with newly diagnosed epilepsy: a randomized and crossover study comparing clinical effects, patient preference and pharmacokinetics.

Authors:  José L Herranz; Rosa Arteaga; Javier Adín; Juan A Armijo
Journal:  Eur J Clin Pharmacol       Date:  2006-08-02       Impact factor: 2.953

Review 2.  Epilepsy.

Authors:  D Chadwick
Journal:  J Neurol Neurosurg Psychiatry       Date:  1994-03       Impact factor: 10.154

3.  Whole-body pharmacokinetics of HDAC inhibitor drugs, butyric acid, valproic acid and 4-phenylbutyric acid measured with carbon-11 labeled analogs by PET.

Authors:  Sung Won Kim; Jacob M Hooker; Nicola Otto; Khaing Win; Lisa Muench; Colleen Shea; Pauline Carter; Payton King; Alicia E Reid; Nora D Volkow; Joanna S Fowler
Journal:  Nucl Med Biol       Date:  2013-07-29       Impact factor: 2.408

4.  A population pharmacokinetic model taking into account protein binding for the sustained-release granule formulation of valproic acid in children with epilepsy.

Authors:  Christelle Rodrigues; Stéphanie Chhun; Catherine Chiron; Olivier Dulac; Elisabeth Rey; Gérard Pons; Vincent Jullien
Journal:  Eur J Clin Pharmacol       Date:  2018-03-21       Impact factor: 2.953

Review 5.  Therapeutic drug monitoring of anticonvulsants. State of the art.

Authors:  I A Choonara; A Rane
Journal:  Clin Pharmacokinet       Date:  1990-04       Impact factor: 6.447

6.  "Therapeutic" serum concentration of phenytoin: the influence of seizure type.

Authors:  D M Turnbull; M D Rawlins; D Weightman; D W Chadwick
Journal:  J Neurol Neurosurg Psychiatry       Date:  1984-03       Impact factor: 10.154

7.  Does valproic acid induce neuroendocrine differentiation in prostate cancer?

Authors:  Abhinav Sidana; Muwen Wang; Wasim H Chowdhury; Antoun Toubaji; Shabana Shabbeer; George Netto; Michael Carducci; Shawn E Lupold; Ronald Rodriguez
Journal:  J Biomed Biotechnol       Date:  2010-10-25

Review 8.  Formation of active metabolites of anticonvulsant drugs. A review of their pharmacokinetic and therapeutic significance.

Authors:  M J Eadie
Journal:  Clin Pharmacokinet       Date:  1991-07       Impact factor: 6.447

Review 9.  Concentration-effect relationships of valproic acid.

Authors:  D W Chadwick
Journal:  Clin Pharmacokinet       Date:  1985 Mar-Apr       Impact factor: 6.447

Review 10.  Clinical pharmacokinetics of valproic acid--1988.

Authors:  G Zaccara; A Messori; F Moroni
Journal:  Clin Pharmacokinet       Date:  1988-12       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.